Ingestible Therapy Activator System and Method

• US 20120109112A1
• Filed: 09/08/2011
• Published: 05/03/2012
• Est. Priority Date: 11/13/2008
• Status: Abandoned Application

• Current Assignee: Proteus Digital Health, Inc. (Otsuka Holdings Company Limited)
• Original Assignee: Proteus Digital Health, Inc. (Otsuka Holdings Company Limited)
• Inventors: Zdeblick, Mark, Jensen, Marc, Colliou, Olivier, Strand, Angela
• Application Number:
  US13/228,344
• Publication Number:
  US 20120109112A1
• Time in Patent Office: Days
• US Class Current: 604/891.1
• CPC Class Codes: A61B 5/073 Intestinal transmitters
• CPC Class Codes: A61J 3/06 into the form of pills, lozenges or dragees
• CPC Class Codes: A61J 3/07 into the form of capsules or similar small containers for oral use
• CPC Class Codes: A61M 31/002 Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50
• CPC Class Codes: A61M 5/1723 using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00
• CPC Class Codes: A61N 1/37217 characterised by the communication link, e.g. acoustic or tactile

Abstract

An ingestible therapy activator system and method are provided. In one aspect, the ingestible therapy activator includes an ingestible device having an effector module to send an effector instruction and a responder module associated with a therapeutic device. The responder module may receive and process the effector instruction, resulting in a response by the therapeutic device. Examples of responses by therapeutic device include activating a therapy, deactivating a therapy, modulating a therapy, and discontinuing a therapy.

Claims

1-12. -12. (canceled)

13. A system for providing instructions to a therapeutic device, the system comprising:

an ingestible device comprising;

a housing; and

an effector module physically associated with the housing for providing an effector instruction, wherein the ingestible device provides the effector instruction to the effector module upon activation in response to occurrence of a desired event; and

a responder module in communication with the therapeutic device for receiving and processing the effector instruction, wherein the effector instruction alters at least an operation of the therapeutic device.

14. The system of claim 13, wherein the effector module comprises a microchip, a power source, and a transmitter.

15. The system of claim 13, wherein the ingestible device comprises at least one of an RFID unit, an antenna, and a coil to communicate the effector instruction.

16. The system of claim 13, further comprising an ingestible medication physically associated with the ingestible device.

17. The system of claim 13, further comprising a placebo structure physically associated with the ingestible device.

18. The system of claim 13, further comprising a receiver physically associated with the responder module.

19. The system of claim 13, wherein the receiver is selected from a group consisting essentially of a receiver adapted to be removably affixed to a living being, a handheld device, an implantable receiver, and a remote device.

20. The system of claim 13, wherein the responder module is physically associated with the therapeutic device.

21. A system for providing instructions to a therapeutic device, the device comprising:

a support structure; and

an effector module physically associated with the support structure for providing an effector instruction,

wherein the device provides the effector instruction to the effector module upon activation in response to occurrence of a desired event; and

the effector module communicates the effector instruction for receipt by a responder module in communication with a therapeutic device, wherein the responder module is operable to process the effector instruction for alteration of at least an operation of the therapeutic device.

22. The system of claim 21, wherein the effector module comprises a microchip, a power source, and a transmitter.

23. The system of claim 21, wherein the ingestible device comprises at least one of an RFID unit, an antenna, and a coil to communicate the effector instruction.

24. The system of claim 21, wherein the ingestible device comprises a power source.

25. The system of claim 21, further comprising an ingestible medication physically associated with the ingestible device.

26. The system of claim 21, further comprising a placebo structure physically associated with the ingestible device.

27. The system of claim 21, wherein the effector instruction comprises at least one of a software instruction, a signal, and data.

28. The system of claim 21, further comprising the responder module and the therapeutic device.

29. The system of claim 28, wherein the responder module comprises a receiver, a microchip, and a transmitter.

30. The system of claim 28, wherein the therapeutic device comprises a cardiac device.

31. The system of claim 30, wherein the therapeutic device comprises at least one of a lead device, and electrode device, a migraine device, a urinary device, and a gastrointestinal device.

32. An ingestible therapy activator comprising:

an ingestible device having an effector module;

an effector instruction generated by the effector module; and

a responder module operable to process the effector instructor and, based on the effector instruction, to generate an alteration of at least an operation of a therapeutic device.